[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100594868":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":10,"locations":22,"responsibleParty":48,"collaborators":53,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":57,"sex":63,"minAge":64,"maxAge":10,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":73,"overallStatus":25,"whyStopped":10,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Medstar Health Research Institute","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":11},"Women >55yo undergoing onabotulinum toxin type A injection for OAB in clinic",null,[12],"Drug: onabotulinum toxin type a",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","onabotulinum toxin type a","All subjects will be scheduled to undergo Onabotulinum toxin type A intradetrusor injection for management of OAB. On Day 0, subjects will undergo Onabotulinum toxin type A injection by a licensed clinical provider and receive a one-time dose of Nitrofurantoin for infection prevention per standard clinic protocol.",[9],[20,21],"Botox","BTX",[23],{"facility":24,"status":25,"city":26,"state":27,"zip":28,"country":29,"countryCode":30,"cosmosGeoPoint":31,"geoPoint":36,"contacts":37},"MedStar Urogynecology Clinic","RECRUITING","Washington D.C.","District of Columbia","20010","United States","US",{"type":32,"coordinates":33},"Point",[34,35],-77.03637,38.89511,{"lat":35,"lon":34},[38,43,45],{"name":39,"role":40,"phone":41,"phoneExt":10,"email":42},"Moriarty","CONTACT","202-748-4112","Patricia.L.Moriarty@medstar.net",{"name":10,"role":40,"phone":10,"phoneExt":10,"email":44},"alexis.a.dieter@medstar.net",{"name":46,"role":47,"phone":10,"phoneExt":10,"email":10},"Alexis Dieter, MD","PRINCIPAL_INVESTIGATOR",{"type":49,"investigatorFullName":50,"investigatorTitle":51,"investigatorAffiliation":52,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Alexis Dieter","Attending Physician","MedStar Health",[54],{"name":5,"class":6},"100594868","assessing-the-genitourinary-microbiome-of-women-with-overactive-bladder-undergoing-onabotulinum-toxin-type-a-intradetrusor-injections-100594868",false,"NCT07025044","Assessing the Genitourinary Microbiome of Women With Overactive Bladder Undergoing Onabotulinum Toxin Type A Intradetrusor Injections","Characterizing the Postmenopausal Genitourinary Microbiome in Women Undergoing Onabotulinum Toxin Type A for Overactive Bladder - A Feasibility Trial","MICROAB_Pilot","Inclusion Criteria:\n\n* Natal female \\> 55 years old\n* English-speaking\n* Scheduled to undergo onabotulinum toxin type A for treatment of OAB\n* No menses for \\>1 year if uterus in situ\n* Planning one dose nitrofurantoin for antibiotic prophylaxis at time of onabotulinum toxin type A injection per clinic protocol\n\nExclusion Criteria:\n\n* Diagnosis of painful bladder syndrome\n* Current symptomatic or clinically-suspected UTI within 30 days prior to onabotulinum toxin type A injection procedure\\*\n* Systemic antibiotic exposure within 30 days\\^\n* Prophylactic antibiotic treatment for recurrent UTI within the last 12 months\n* Current systemic immunosuppressive therapy (i.e. prednisone or immunomodulators) immunotherapy, chemotherapy or radiation treatment\n* Prior pelvic radiation\n* Indwelling catheter or intermittent catheterization","FEMALE","55 Years",{"count":66,"type":67},40,"ESTIMATED","OBSERVATIONAL","Single-site prospective observational pilot feasibility study of women with overactive bladder\u002Furge urinary incontinence undergoing onabotulinum toxin type A intradetrusor injections in order to achieve the following objectives:\n\n* Establish a record of successful collaboration with Dr. Ravel, an expert researcher in the female microbiome based at the University of Maryland\n* Demonstrate the investigators' ability to recruit subjects from the diverse population of postmenopausal women undergoing BTX for OAB within MedStar Health Urogynecology clinics\n* Collect, process and analyze urine specimens collected prior to and 4-weeks after BTX injection, and to compare the GU microbiome of self-collected versus clinic-collected samples\n* Assess response to BTX treatment and explore rates of and risk factors for urinary tract infection and incomplete voiding requiring catheterization within the first 4-weeks after BTX",[71,72],"Overactive Bladder (OAB)","Urge Incontinence",[74],"onabotulinum toxin type A","2025-09-08",{"date":77,"type":78},"2025-09-12","ACTUAL",{"date":80,"type":78},"2025-09-03",{"date":82,"type":67},"2026-06-01",{"name":50,"class":6},1]